RxDoctor Payments Data

David Thordarson, MD

Orthopaedic Surgery · Los Angeles, CANPI 1457363798

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $2,200,000 of the $2,532,991 with a category attached, or 86.9%. Paragon 28, Inc. accounts for 89.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2020 at $2,209,968 and has fallen 96.4% since, to $79,640 in 2025. Among orthopaedic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,532,991in general payments, 2019–2025

Across 201 payments — averaging $12,602 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paragon 28, Inc.$2.3M
  • Extremity Medical$110K
  • Ortho Solutions Inc$59K
  • Stryker$51K
  • Orthofix Medical, Inc.$23K
  • Trilliant Surgical LLC.$12K
  • plus $12K from 13 others
$75,945in research payments, 2019–2025

Across 8 payments — averaging $9493.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Paragon 28, Inc.$55K
  • Stryker$21K
$833in ownership & investment interests, 2019–2025

Across 3 payments — averaging $277.78 each. An ownership or investment interest held by the physician or an immediate family member.

  • Extremity Medical$833
  • Paragon 28, Inc.$0

What the payments were for

  • Royalty or licence$74,0393%
  • Consulting fees$228,0819%
  • Grants$5,0000%
  • Travel & lodging$19,7381%
  • Food & beverage$5,1140%
  • Education$1,0190%
  • Ownership interest$2,200,00087%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,532,991 in reported general payments places this provider in the 95th percentile of 1,808 orthopaedic surgery providers in California.

See all orthopaedic surgery providers in California

Medicare billing

Part B allowed, 2024
$321,727
Medicare patients
811
Services billed
2,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib19$2,201
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen68$1,096
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$495
Gabapentin46$439
Diclofenac Sodium21$351
Doxycycline Hyclate38$278
Ibuprofen17$126
Meloxicam37$69

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →